Compare PEW & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PEW | IBIO |
|---|---|---|
| Founded | 2007 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.7M | 52.8M |
| IPO Year | 2025 | 2009 |
| Metric | PEW | IBIO |
|---|---|---|
| Price | $1.61 | $0.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $5.69 |
| AVG Volume (30 Days) | 405.6K | ★ 470.8K |
| Earning Date | 11-12-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 81.71 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $96,449,000.00 | N/A |
| Revenue This Year | $6.38 | N/A |
| Revenue Next Year | $6.53 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 3.57 | N/A |
| 52 Week Low | $1.76 | $0.69 |
| 52 Week High | $3.97 | $3.82 |
| Indicator | PEW | IBIO |
|---|---|---|
| Relative Strength Index (RSI) | 25.68 | 37.67 |
| Support Level | N/A | $0.71 |
| Resistance Level | $2.20 | $0.85 |
| Average True Range (ATR) | 0.12 | 0.06 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 0.70 | 16.94 |
GrabAGun Digital Holdings Inc is a multi-brand eCommerce retailer of firearms, ammunition and related accessories. The Company's firearm products are ordered and paid for by customers online through the Company's eCommerce site and mobile app and are delivered to them on-premises through their choice of federal firearm licensed dealers nationwide. The Company's network of localized firearm dealers perform background checks on firearms purchasers and complete sales forms as mandated by federal and state firearm regulations.
iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. Its product candidate pipeline includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, growth differentiation factor 11 (GDF11), and Activin A; IBIO-600; Amylin Antibody; and Target 4, in different stages of development, being developed as potential therapies for obesity and cardiometabolic disease. The company operates as one reportable segment, which is that of a biotechnology company leveraging AI and ML for the development of hard-to-drug precision antibodies.